The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

R-Bendamustine is an effective treatment for follicular lymphoma (FL). Previous large trials demonstrated the prognostic role of the molecular minimal residual disease (MRD) during the most frequently adopted chemotherapeutic regimens, but there are not yet conclusive data about the effect of combin...

Full description

Bibliographic Details
Main Authors: Sara Galimberti, Elena Ciabatti, Giacomo Ercolano, Susanna Grassi, Francesca Guerrini, Nadia Cecconi, Martina Rousseau, Giulia Cervetti, Francesco Mazziotta, Lorenzo Iovino, Franca Falzetti, Flavio Falcinelli, Alberto Bosi, Luigi Rigacci, Sofia Kovalchuk, Daniele Vallisa, Lucia Macchia, Eugenio Ciancia, Mario Petrini
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-06-01
Series:Frontiers in Pharmacology
Subjects:
MRD
follicular lymphoma
bendamustine
BCL2/IGH
rituximab
PCR
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00413/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00413/full

Similar Items